Loading
Immunomedics developed Trodelvy (sacituzumab govitecan), an antibody that carries chemotherapy to cancer cells carrying a protein called Trop-2, first approved for triple-negative breast cancer. Gilead bought the company in 2020.
Immunomedics, Inc. (formerly Nasdaq: IMMU), of Morris Plains, New Jersey, developed antibody-drug conjugates using a linker that releases its payload without needing an enzyme, so the drug also reaches neighbouring tumour cells. Its lead product, Trodelvy (sacituzumab govitecan-hziy), a Trop-2-directed ADC, received FDA accelerated approval in April 2020 for adults with metastatic triple-negative breast cancer after at least two prior therapies for metastatic disease, and the phase 3 ASCENT study had been stopped early for efficacy. Gilead agreed on 13 September 2020 to buy Immunomedics for USD 88 per share in cash, valuing it at about USD 21 billion, and the merger was completed on 23 October 2020.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · Gilead's announcement of 13 September 2020, filed as exhibit 99.1 to Immunomedics' 8-K: USD 88.00 per share in cash, approximately USD 21 billion | 2020 | $21B | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2020-09-13 | Immunomedics to Gilead Sciences (incl. Kite) Sacituzumab govitecan (Trodelvy), TROP2 ADC | Acquisition | not disclosed | $21bn | source |
Sacituzumab govitecan carries chemotherapy to cancer cells bearing TROP2. It is FDA-approved for specific advanced breast-cancer settings, including two first-line triple-negative indications.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC).
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Antibody-drug conjugate (ADC).
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Antibody-drug conjugate (ADC).
Shares Sacituzumab govitecan, TROP2.
Shares Sacituzumab govitecan, TROP2, Antibody-drug conjugate (ADC).
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, TROP2, Antibody-drug conjugate (ADC).
Shares Sacituzumab govitecan, TROP2, Antibody-drug conjugate (ADC).
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, TROP2, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/